Decision

Abbvie Corporation v. Samsung Bioepis Co., 2017 FC 676 (Adalimumab*)

Justice Manson - 2017-07-25

Read full decision. Automatically generated summary:

There are three applications by the Applicants, AbbVie Corporation and AbbVie Biotechnology Ltd (together, “AbbVie”), for an Order pursuant to Rules 3, 55, 306, 307, and 385(1)(a) of the Federal Court Rules requiring the Respondents, Samsung Bioepis, Ltd. (“Bioepis”), to reverse the order of the Parties’ evidence and serve its evidence on the issues of (1) claim relevancy, (2) priority date entitlement, and (3) material misrepresentation before AbbVie is required to deliver its evidence on those issues. The Applicants’ also seek their costs of the motion.

Decision relates to:

  • T-598-17 - ABVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO. LTD. ET AL
  • T-599-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD.ET AL
  • T-600-17 - ABBVIE CORPORATION ET AL
  • T-601-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO LTD ET AL
  • T-602-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD. ET AL
  • T-603-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD. ET AL
  • T-604-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD.ET AL
  • T-605-17 - ABBVIE CORPORATION ET AL v. SAMSUNG BIOEPIS CO., LTD.ET AL

 

Canadian Intellectual Property